Reoxygenation during radiotherapy in intermediate-risk prostate cancer

Radiother Oncol. 2019 Apr:133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12.

Abstract

Hypoxia is a major risk factor of prostate cancer radioresistance. We evaluated hypoxia non-invasively, using 18F-Misonidazole PET/CT prior to radiotherapy and after a dose of 20 Gy in intermediate-risk prostate cancer patients. Decreased hypoxic volumes were observed in all patients, suggesting that radiotherapy induces early prostate tumor reoxygenation.

Keywords: Dose painting radiotherapy; FAZA; IMRT; Misonidazole; Radioresistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Hypoxia / drug effects
  • Cell Hypoxia / radiation effects*
  • Fluorine Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Misonidazole / administration & dosage
  • Oxygen / metabolism
  • Positron Emission Tomography Computed Tomography
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiopharmaceuticals / administration & dosage
  • Radiotherapy, Intensity-Modulated
  • Retrospective Studies

Substances

  • Fluorine Radioisotopes
  • Radiation-Sensitizing Agents
  • Radiopharmaceuticals
  • Misonidazole
  • Fluorine-18
  • Oxygen